rebel Financial rebel Financial
← All Posts

AstraZeneca PLC

April 09, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended December 31, 2025 ✓ For
2 To confirm the 2025 interim dividends ✓ For
3 To appoint KPMG LLP as Auditor ✓ For
4 To authorize the Directors to agree the remuneration of the Auditor ✓ For
5 To re-elect the following Directors:
5a Michel Demaré ✓ For
5b Pascal Soriot ✗ Against
5c Aradhana Sarin ✗ Against
5d Philip Broadley ✓ For
5e Euan Ashley ✓ For
5f Birgit Conix ✓ For
5g Rene Haas ✓ For
5h Karen Knudsen ✓ For
5i Diana Layfield ✓ For
5j Anna Manz ✓ For
5k Sheri McCoy ✓ For
5l Tony Mok ✓ For
5m Marcus Wallenberg ✗ Against
6 To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended December 31, 2025 ✓ For
7 To renew the authorization to grant awards under the French Appendix 3 of the AstraZeneca Performance Share Plan 2020 ✓ For
8 To authorize limited political donations ✓ For
9 To authorize the Directors to allot shares ✓ For
10 To authorize the Directors to disapply pre-emption rights* ✓ For
11 To authorize the Directors to further disapply pre-emption rights for acquisitions and specified capital investments* ✓ For
12 To authorize the Company to purchase its own shares* ✓ For
13 To reduce the notice period for general meetings* ✓ For
Attachments
📄
AstraZeneca_Notice_of_Meeting.pdf 1.2 MB
📄
AstraZeneca_Annual_Report_2025.pdf 11.2 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.